John Prichard, MD
Family Medicine · Ventura, CANPI 1477617546
Payments from drug & device makers
Across 231 payments — averaging $438.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- Gilead$22K
- Pfizer$8K
- Bristol Myers Squibb$5K
- Janssen Scientific Affairs, LLC$5K
- AstraZeneca$4K
- plus $16K from 25 others
What the payments were for
- Consulting fees$28,78528%
- Speaking & faculty fees$55,33455%
- Travel & lodging$9,1749%
- Food & beverage$7,5227%
- Education$4220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $41,065 |
| Gilead(2 entities) | 49 | $22,299 |
| Pfizer | 6 | $7,571 |
| Bristol Myers Squibb | 12 | $5,125 |
| Janssen Scientific Affairs, LLC | 6 | $4,622 |
| AstraZeneca(2 entities) | 22 | $4,437 |
| Viiv Healthcare Company | 15 | $4,393 |
| Blueprint Medicines Corporation | 10 | $3,858 |
| Sanofi | 9 | $3,468 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,441 |
| Incyte Corporation | 7 | $509 |
| Merck | 12 | $380 |
| Beigene USA, Inc. | 5 | $303 |
| GSK | 2 | $241 |
| Apellis Pharmaceuticals, Inc. | 2 | $192 |
| Seagen Inc. | 4 | $186 |
| ADC Therapeutics America, Inc. | 2 | $161 |
| Lilly USA, LLC | 3 | $128 |
| Amgen | 1 | $125 |
| Janssen Products, LP | 1 | $122 |
| Johnson & Johnson(2 entities) | 14 | $106 |
| Paratek Pharmaceuticals, Inc. | 1 | $102 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $99 |
| Genmab U.S., Inc. | 1 | $98 |
| Karyopharm Therapeutics Inc. | 2 | $49 |
| AbbVie | 2 | $40 |
| Sobi, Inc | 2 | $38 |
| Array Biopharma Inc | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $21 |
| CTI Biopharma Corp. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$101,236 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 29 | $502,274 |
| AyvakitAvapritinib | 11 | $429,588 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 107 | $419,331 |
| VenclextaVenetoclax | 36 | $389,827 |
| PromactaEltrombopag Olamine | 25 | $287,674 |
| ProcritEpoetin Alfa | 90 | $286,873 |
| JakafiRuxolitinib Phosphate | 15 | $246,733 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 58 | $220,696 |
| BosulifBosutinib | 11 | $216,566 |
| NinlaroIxazomib Citrate | 14 | $179,085 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 41 | $175,910 |
| CalquenceAcalabrutinib Maleate | 11 | $169,107 |
| CabenuvaCabotegravir/Rilpivirine | 15 | $105,432 |
| IsentressRaltegravir Potassium | 55 | $102,404 |
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $79,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $22,299 | $557,211158 claims |
| Bristol Myers SquibbRevlimid | $5,125 | $502,27429 claims |
| Blueprint Medicines CorporationAyvakit | $3,858 | $429,58811 claims |
| AbbVieVenclexta | $40 | $389,82736 claims |
| Johnson & JohnsonProcrit, Complera, Prezcobix | $106 | $364,757117 claims |
| Viiv Healthcare CompanyTriumeq, Cabenuva, Dovato | $4,393 | $345,43678 claims |
| Incyte CorporationJakafi | $509 | $246,73315 claims |
| PfizerBosulif | $7,571 | $216,56611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $41,065 | $179,08514 claims |
| AstraZenecaCalquence | $4,437 | $169,10711 claims |
| MerckIsentress | $380 | $102,40455 claims |
| Janssen Products, LPSymtuza | $122 | $55,57112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Ventura
- Robert WilliamsVentura$1.4M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.